GlassScriptPhysician profile
Ndeye Kone
NPI 1073832028
$12,771.43
in general payments reported to CMS, 2019-2025
28 companies · $3,034 in 2025
The $3,034 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,473 · 2022: $2,594 · 2023: $2,233 · 2024: $2,438 · 2025: $3,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,705.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,027.65 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,092.68 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,446.55 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $1,020.34 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $733.26 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $668.88 | 2021-2024 | Zeposia |
| Pfizer INC. | $645.14 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $499.08 | 2021-2024 | Rebyota |
| Genzyme Corporation | $452.62 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $283.97 | 2021-2023 | |
| Ardelyx, INC. | $256.32 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $232.14 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $170.57 | 2021-2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $161.12 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $158.62 | 2024-2025 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $158.42 | 2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $135.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $105.83 | 2021-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $105.77 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $90.96 | 2023-2025 | Voquezna |
| Celltrion USA INC. | $52.40 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $52.03 | 2021 | |
| Boston Scientific Corporation | $51.73 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Gilead Sciences, INC. | $48.51 | 2023-2024 | |
| Novo Nordisk INC | $46.80 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $31.62 | 2021-2024 | Givlaari |
| Intercept Pharmaceuticals, INC. | $24.86 | 2023 | Ocaliva |
| Tersera Therapeutics LLC | $18.07 | 2025 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ndeye Kone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.